Corline Biomedical AB (STO:CLBIO)
17.60
+0.05 (0.28%)
Jul 24, 2026, 3:35 PM CET
Corline Biomedical AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 32.9 | 20.56 | 17.67 | 17.01 | 26.21 | 41.64 |
Cash & Short-Term Investments | 32.9 | 20.56 | 17.67 | 17.01 | 26.21 | 41.64 |
Cash Growth | 180.38% | 16.35% | 3.86% | -35.09% | -37.05% | 367.55% |
Accounts Receivable | 5.48 | 1.6 | 1 | 2.93 | 1.66 | 2.3 |
Other Receivables | 0.8 | 0.71 | 1.63 | 2.29 | 6.82 | 0.47 |
Total Trade Receivables | 6.29 | 2.31 | 2.63 | 5.22 | 8.47 | 2.77 |
Inventory | 0.82 | - | - | - | - | - |
Other Current Assets | 1.02 | 1.12 | 0.75 | 1.57 | 1.31 | 0.42 |
Total Current Assets | 41.03 | 23.98 | 21.04 | 23.8 | 36 | 44.82 |
Net Property, Plant & Equipment | 0.5 | 0.16 | 0.22 | 0.31 | 0.28 | 0.18 |
Other Intangible Assets | 74.45 | 74.43 | 73.5 | 75.99 | 65.5 | 56.66 |
Long-Term Investments | - | 0 | 0 | 0 | 0 | 0 |
Total Assets | 115.97 | 98.58 | 94.76 | 100.11 | 101.78 | 101.66 |
Accounts Payable | 1.15 | 0.93 | 3.09 | 1.97 | 4.34 | 1.96 |
Accrued Expenses | 3.78 | 3.18 | 2.85 | 3.53 | 2.45 | 4.56 |
Other Current Liabilities | 1.48 | 0.71 | 1.91 | 1.29 | 0.4 | 2.91 |
Total Current Liabilities | 6.4 | 4.82 | 7.85 | 6.79 | 7.19 | 9.43 |
Other Long-Term Liabilities | 18.26 | - | - | - | - | - |
Total Long-Term Liabilities | 18.26 | - | - | - | - | - |
Total Liabilities | 24.66 | 4.82 | 7.85 | 6.79 | 7.19 | 9.43 |
Common Stock | - | 3.2 | 3.06 | 2.69 | 2.69 | 2.69 |
Additional Paid-in Capital | - | 192.81 | 171.39 | 155.19 | 155.19 | 155.19 |
Accumulated Other Comprehensive Income | - | 61.52 | 60.58 | 63.08 | 52.59 | 43.75 |
Retained Earnings | - | -163.77 | -148.12 | -127.64 | -115.88 | -109.39 |
Total Common Shareholders' Equity | - | 93.76 | 86.91 | 93.32 | 94.59 | 92.23 |
Shareholders' Equity | 100.45 | 93.76 | 86.91 | 93.32 | 94.59 | 92.23 |
Total Liabilities & Equity | 115.97 | 98.58 | 94.76 | 100.11 | 101.78 | 101.66 |
Net Cash (Debt) | 32.9 | 20.56 | 17.67 | 17.01 | 26.21 | 41.64 |
Net Cash Growth | 60.07% | 16.35% | 3.86% | -35.09% | -37.05% | 367.55% |
Net Cash Per Share | 1.31 | 0.83 | 0.81 | 0.79 | 1.19 | 2.04 |
Book Value | - | 93.76 | 86.91 | 93.32 | 94.59 | 92.23 |
Book Value Per Share | - | 3.79 | 3.98 | 4.34 | 4.30 | 4.51 |
Tangible Book Value | -74.45 | 19.33 | 13.42 | 17.32 | 29.09 | 35.58 |
Tangible Book Value Per Share | -2.98 | 0.78 | 0.62 | 0.81 | 1.32 | 1.74 |